ArticleExperimental & molecular medicine2017
Stimulation of osteoclast migration and bone resorption by C-C chemokine ligands 19 and 21.
Article in Experimental & molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Insights into the mechanism of vascular endothelial cells on bone biology.Bioscience reports · 2021Pooled it
- Spatiotemporal Sonodynamic-Nanozymic Therapy for Infected Jawbone Defects.Advanced healthcare materials · 2026Article
- Article
- Exosomal lncRNA SILC1 from bicalutamide-activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis.Journal of translational medicine · 2026Article
- [A Study on the Relationship Between Cyclic Inflammatory Protein Fibroblast Growth Factor 21, Osteoporosis, and Fractures].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- Identification of candidate biomarkers for diagnosis, disease activity, and relapse prediction in IgG4-related disease.Arthritis research & therapy · 2026Article
- Lymphatic vascular aging and age-related bone loss: current status and future perspectives.Frontiers in immunology · 2026Review
- Association between novel inflammatory indices and osteoporosis among older adults: evidence from a large multicenter study in China.Frontiers in medicine · 2026Article
- Progress in research on osteoporosis secondary to SARS-CoV-2 infection.Animal models and experimental medicine · 2025Review
- Quercetagetin alleviates inflammatory osteoclastogenesis and collagen antibody-induced arthritis via Nrf2 signaling and Pten/AKT/Nfatc1 axis.Arthritis research & therapy · 2025Article
- Targeting BRD4 to attenuate RANKL-induced osteoclast activation and bone erosion in rheumatoid arthritis.Molecular and cellular biochemistry · 2025Article
- Norwogonin Attenuates Inflammatory Osteolysis and Collagen-Induced Arthritis via Modulating Redox Signalling and Calcium Oscillations.Journal of cellular and molecular medicine · 2025Article
- Targeting chemokine signaling networks for therapeutics in skeletal disorders.Frontiers in endocrinology · 2025Review
- Oxidative stress and inflammation: roles in osteoporosis.Frontiers in immunology · 2025Review
- From death to birth: how osteocyte death promotes osteoclast formation.Frontiers in immunology · 2025Review
- Extracellular derivatives for bone metabolism.Journal of advanced research · 2024Review
- The Role of TAM Receptors in Bone.International journal of molecular sciences · 2023Review
- It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.Blood advances · 2023Review
- CC chemokines and receptors in osteoarthritis: new insights and potential targets.Arthritis research & therapy · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoclasts are responsible for the bone erosion associated with rheumatoid arthritis (RA). The upregulation of the chemokines CCL19 and CCL21 and their receptor CCR7 has been linked to RA pathogenesis. The purpose of this study was to evaluate the effects of CCL19 and CCL21 on osteoclasts and to reveal their underlying mechanisms. The expression of CCL19, CCL21 and CCR7 was higher in RA patients than in osteoarthritis patients. In differentiating osteoclasts, tumor necrosis factor-α, interleukin-1β and lipopolysaccharide stimulated CCR7 expression. CCL19 and CCL21 promoted osteoclast migration and resorption activity. These effects were dependent on the presence of CCR7 and abolished by the inhibition of the Rho signaling pathway. CCL19 and CCL21 promoted bone resorption by osteoclasts in an in vivo mice calvarial model. These findings demonstrate for the first time that CCL19, CCL21 and CCR7 play important roles in bone destruction by increasing osteoclast migration and resorption activity. This study also suggests that the interaction of CCL19 and CCL21 with CCR7 is an effective strategic focus in developing therapeutics for alleviating inflammatory bone destruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.